This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
The historical rank and industry rank for Quest Diagnostics's Median PS Value or its related term are showing as below:
DGX'
s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.99 Med: 1.16 Max: 1.38
Current: 1.08
During the past 13 years, the highest Price to Median PS Value of Quest Diagnostics was 1.38. The lowest was 0.99. And the median was 1.16.
DGX's Price-to-Median-PS-Value is ranked worse than 73.17% of 82
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.805
vs DGX: 1.08
Quest Diagnostics Median PS Value Historical Data
The historical data trend for Quest Diagnostics's Median PS Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Quest Diagnostics's Median PS Value
For the Diagnostics & Research subindustry, Quest Diagnostics's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Quest Diagnostics's Price-to-Median-PS-Value Distribution in the Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Quest Diagnostics's Price-to-Median-PS-Value distribution charts can be found below:
* The bar in red indicates where Quest Diagnostics's Price-to-Median-PS-Value falls into.
10-Year Median PS Ratio is 1.7493.
Quest Diagnostics's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $87.14.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics (NYSE:DGX) Median PS Value Explanation
This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio
is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.
It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.
Quest Diagnostics's Price to Median PS Value for today is calculated as
Price to Median PS Value
=
Share Price
/
Median PS Value
=
164.18
/
152.43
=
1.08
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Quest Diagnostics Median PS Value Related Terms
Thank you for viewing the detailed overview of Quest Diagnostics's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.
Quest Diagnostics Inc is a leading independent provider of diagnostic testing, information, and services in the us. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk-assessment services, and information technology solutions.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
DGX has been successfully added to your 